Literature DB >> 19726160

Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism.

Ulf de Faire1, Jun Su, Xiang Hua, Anna Frostegård, Mats Halldin, Mai-Lis Hellenius, Max Wikström, Ingrid Dahlbom, Hans Grönlund, Johan Frostegård.   

Abstract

OBJECTIVE: We here determine the role of IgM antibodies against phosphorylcholine (anti-PC) in prediction of cardiovascular disease (CVD) and on macrophage uptake of Oxidized LDL (OxLDL).
METHODS: From a screening of 4232 subjects, 60-year-old (2039 men and 2193 women), 211 incident cases of CVD (myocardial infarction, ischemic stroke, or hospitalized angina pectoris) and 633 age- and sex-matched controls were identified through a 5-7 year follow-up. Serum levels of IgM anti-PC was determined by ELISA. Anti-PC was extracted from pooled human IgM and the effect of anti-PC on the uptake of OxLDL was studied by FACScan.
RESULTS: Relative risks (RR) with 95% confidence intervals (CI) by quartiles of anti-PC levels with quartile 4 set as the reference value (RR = 1.0) and adjusted for smoking, BMI, type II diabetes, hypercholesterolaemia, and high blood pressure yielded an excess risk for CVD only for those within the lowest quartile of anti-PC values with an RR of 1.37 (CI 0.87-2.16). However, for men stronger associations were noted with increasing multivariately adjusted RRs from quartile 4 to quartile 1. Subjects within quartile 1 (values below 29.7 U/ml) had a significantly increased RR of 1.96 (CI 1.09-3.55). Further adjustments for hsCRP gave essentially the same results. No excess risk was noted for women. Specific anti-PC could be extracted from IgM and these antibodies inhibited macrophage uptake of OxLDL.
CONCLUSIONS: Low IgM anti-PC could be a novel risk marker for CVD among men. One possible mechanism could be inhibition of uptake of oxLDL in macrophages. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19726160     DOI: 10.1016/j.jaut.2009.05.003

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  41 in total

Review 1.  Auto-antibodies as emergent prognostic markers and possible mediators of ischemic cardiovascular diseases.

Authors:  P Roux-Lombard; S Pagano; F Montecucco; N Satta; N Vuilleumier
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

2.  Senescent cells expose and secrete an oxidized form of membrane-bound vimentin as revealed by a natural polyreactive antibody.

Authors:  David Frescas; Christelle M Roux; Semra Aygun-Sunar; Anatoli S Gleiberman; Peter Krasnov; Oleg V Kurnasov; Evguenia Strom; Lauren P Virtuoso; Michelle Wrobel; Andrei L Osterman; Marina P Antoch; Vadim Mett; Olga B Chernova; Andrei V Gudkov
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-13       Impact factor: 11.205

Review 3.  Protective autoantibodies in the rheumatic diseases: lessons for therapy.

Authors:  Gregg J Silverman; Jaya Vas; Caroline Grönwall
Journal:  Nat Rev Rheumatol       Date:  2013-03-19       Impact factor: 20.543

Review 4.  Protective natural autoantibodies to apoptotic cells: evidence of convergent selection of recurrent innate-like clones.

Authors:  Gregg J Silverman
Journal:  Ann N Y Acad Sci       Date:  2015-05-18       Impact factor: 5.691

5.  Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease.

Authors:  Christian A Gleissner; Christian Erbel; Julia Haeussler; Mohammadreza Akhavanpoor; Gabriele Domschke; Fabian Linden; Andreas O Doesch; Göran Conradson; Sebastian J Buss; Nina P Hofmann; Gitsios Gitsioudis; Hugo A Katus; Grigorios Korosoglou
Journal:  Clin Res Cardiol       Date:  2014-08-08       Impact factor: 5.460

6.  In old BALB/c mice, bone marrow pre-B cell and surrogate light chain reduction is associated with increased B cell reactivity to phosphorylcholine, but reduced T15 idiotype dominance.

Authors:  Kelly Khomtchouk; Sarah Alter; Michelle Ratliff; Bonnie B Blomberg; Richard L Riley
Journal:  Mech Ageing Dev       Date:  2016-11-19       Impact factor: 5.432

7.  A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia.

Authors:  Xu Chen; Stefan Gustafsson; Thomas Whitington; Yan Borné; Erik Lorentzen; Jitong Sun; Peter Almgren; Jun Su; Robert Karlsson; Jie Song; Yi Lu; Yiqiang Zhan; Sara Hägg; Per Svensson; Karin E Smedby; Susan L Slager; Erik Ingelsson; Cecilia M Lindgren; Andrew P Morris; Olle Melander; Thomas Karlsson; Ulf de Faire; Kenneth Caidahl; Gunnar Engström; Lars Lind; Mikael C I Karlsson; Nancy L Pedersen; Johan Frostegård; Patrik K E Magnusson
Journal:  Hum Mol Genet       Date:  2018-05-15       Impact factor: 6.150

8.  Nontypeable Haemophilus influenzae Invasive Blood Isolates Are Mainly Phosphorylcholine Negative and Show Decreased Complement-Mediated Killing That Is Associated with Lower Binding of IgM and CRP in Comparison to Colonizing Isolates from the Oropharynx.

Authors:  Jeroen D Langereis; Amelieke J H Cremers; Marloes Vissers; Josine van Beek; Jacques F Meis; Marien I de Jonge
Journal:  Infect Immun       Date:  2019-01-24       Impact factor: 3.441

9.  Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.

Authors:  Bram J Geller; Jessica L Mega; David A Morrow; Jianping Guo; Elaine B Hoffman; C Michael Gibson; Christian T Ruff
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

10.  Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality.

Authors:  A G Frostegård; X Hua; J Su; J J Carrero; O Heimbürger; P Bárány; P Stenvinkel; J Frostegård
Journal:  Clin Exp Immunol       Date:  2013-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.